The interaction of substrate-related ketals with bacterial and viral neuraminidases
Abstract:
Arthrobacter sialophilus neuraminidase catalyzes the hydration of 5-acetamido-2,6-anhydro-3,5-dideoxy-D-glycero-D-galacto-non-2-enonic acid (2,3-dehydro-AcNeu) with Km and kcat values of 8.9 X 10(-4) M and 6.40 X 10(-4) s-1, respectively. The methyl ester of 2,3-dehydro-AcNeu as well as 2,3-dehydro-4-epi-AcNeu are also hydrated by the enzyme. The product resulting from the enzymatic hydration of 2,3-dehydro-AcNeu is N-acetylneuraminic acid. A series of derivatives of 2,3-dehydro-AcNeu (K1, 1.60 X 10(-6) M) including 2,3-dehydro-4-epi-AcNeu (2.10 X 10(-4) M) and 2,3-dehydro-4-keto-AcNeu (K1 = 6.10 X 10(-5) M) were each competitive inhibitors of the enzyme. The methyl esters of these ketal derivatives were also competitive enzyme inhibitors. Dissociation constants for these ketals were determined independently by fluorescence enzyme titrations which gave values similar to those found kinetically. These six relatives of 2,3-dehydro-AcNeu were also competitive inhibitors for the influenza viral neuraminidases. For the viral neuraminidases, the dissociation constant for 2,3-dehydro-AcNeu and its methyl ester were 2.40 X 10(-6) and 1.17 X 10(-3) M, respectively. The interpretation placed upon the K1 values determined for these ketals against the Arthrobacter versus influenza neuraminidases is that the bacterial enzyme has a more flexible glycone binding site.
Related Concept Videos
SN1 Reaction: Kinetics
However, Sir Christopher Ingold and Edward D. Hughes, who studied the kinetics of various nucleophilic substitution reactions, noticed that a tertiary alkyl halide does undergo a nucleophilic substitution reaction in the presence of a weak nucleophile. While studying the substitution...
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Predicting Products: Substitution vs. Elimination
The following factors can influence the mechanisms competing against each other:
Influenza
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors


